18:58 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Feb....
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
00:38 , Nov 13, 2018 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
18:36 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA GI panel backs Pfizer's Xeljanz for ulcerative colitis

FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously in favor of approving twice-daily 10 mg Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The panel also voted 8-7...
22:42 , Mar 8, 2018 |  BC Extra  |  Company News

FDA GI panel backs Xeljanz for UC

FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously in favor of approving twice-daily 10 mg Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The panel also voted 8-7...
08:17 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

FDA panel to discuss Pfizer's Xeljanz for UC

FDA's Gastrointestinal Drugs Advisory Committee will meet on March 8 to discuss an sNDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib tablets to treat adults with moderate to severe active ulcerative colitis. In December, FDA...
21:34 , Jan 19, 2018 |  BC Extra  |  Company News

FDA panel to discuss Pfizer's Xeljanz in UC

FDA's Gastrointestinal Drugs Advisory Committee will meet on March 8 to discuss an sNDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib tablets to treat adults with moderate to severe active ulcerative colitis. In December, FDA...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp. ’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to...
00:23 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

FDA to discuss Xeljanz sNDAs in psoriatic arthritis, accepts UC sNDA

FDA’s Arthritis Advisory Committee will meet on Aug. 3 to discuss sNDAs from Pfizer Inc. (NYSE:PFE) for Xeljanz (Jaquinus) tofacitinib and Xeljanz XR extended release to treat adults with active psoriatic arthritis. Pfizer said FDA...
21:19 , Apr 25, 2017 |  BC Extra  |  Financial News

Sienna's series B round brings in $40M

Dermatology company Sienna Biopharmaceuticals Inc. (Westlake Village, Calif.) raised $40 million in a series B round led by Arch Venture Partners and Venvest Capital. Also participating were Partner Fund Management, Altitude Life Science Ventures, former...